Novel blood-based biomarkers can signal the presymptomatic stage of genetic frontotemporal dementia

Takeaway

  • Blood levels of neurofilament light and phosphorylated neurofilament heavy chains distinguish the conversion from presymptomatic to symptomatic frontotemporal dementia.

Why this matters

  • Although the identification of presymptomatic stages of frontotemporal dementia enables earlier interventions, more accessible and accurate biomarkers are needed.

  • This novel study provides a biomarker-based stratification and biomarker cascade of the conversion stage which reflects the most treatment-relevant stage within the presymptomatic phase; this could facilitate a biomarker-based approach to genetic frontotemporal dementia and the development of future disease modifying therapies.